
CymaBay Therapeutics has announced positive topline results from its phase 3 RESPONSE study which assessed the safety and efficacy of …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ

